These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7859808)

  • 1. Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
    Port RE; Schlemmer HP; Bachert P
    Eur J Clin Pharmacol; 1994; 47(2):187-93. PubMed ID: 7859808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
    Schlemmer HP; Bachert P; Semmler W; Hohenberger P; Schlag P; Lorenz WJ; van Kaick G
    Magn Reson Imaging; 1994; 12(3):497-511. PubMed ID: 8007780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.
    Kissel J; Brix G; Bellemann ME; Strauss LG; Dimitrakopoulou-Strauss A; Port R; Haberkorn U; Lorenz WJ
    Cancer Res; 1997 Aug; 57(16):3415-23. PubMed ID: 9270007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian method for predicting 5-fluorouracil pharmacokinetic parameters following short-term infusion in patients with colorectal cancer.
    Climente-Martí M; Merino-Sanjuán M; Almenar-Cubells D; Jiménez-Torres NV
    J Pharm Sci; 2003 Jun; 92(6):1155-65. PubMed ID: 12761805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
    Rengelshausen J; Hull WE; Schwenger V; Göggelmann C; Walter-Sack I; Bommer J
    Am J Kidney Dis; 2002 Feb; 39(2):E10. PubMed ID: 11840401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
    Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
    Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mathematical model of the kinetics of 5-fluorouracil and its metabolites in cancer patients.
    Coustère C; Mentré F; Sommadossi JP; Diasio RB; Steimer JL
    Cancer Chemother Pharmacol; 1991; 28(2):123-9. PubMed ID: 2060083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolites of 5-fluorouracil in plasma and urine, as monitored by 19F nuclear magnetic resonance spectroscopy, for patients receiving chemotherapy with or without methotrexate pretreatment.
    Hull WE; Port RE; Herrmann R; Britsch B; Kunz W
    Cancer Res; 1988 Mar; 48(6):1680-8. PubMed ID: 3125967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kinetic modeling of in vivo--nuclear magnetic resonance spectroscopy data: 5-fluorouracil in liver and liver tumors.
    Port RE; Bachert P; Semmler W
    Clin Pharmacol Ther; 1991 May; 49(5):497-505. PubMed ID: 1903099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
    Kissel J; Port RE; Zaers J; Bellemann ME; Strauss LG; Haberkorn U; Brix G
    Med Phys; 1999 Apr; 26(4):609-15. PubMed ID: 10227363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 19F-[1H] nuclear Overhauser effect and proton decoupling of 5-fluorouracil and alpha-fluoro-beta-alanine.
    Krems B; Bachert P; Zabel HJ; Lorenz WJ
    J Magn Reson B; 1995 Aug; 108(2):155-64. PubMed ID: 7648013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
    Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
    NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 5-fluorouracil pharmacokinetics following intraperitoneal and intravenous administration using in vivo 19F magnetic resonance spectroscopy.
    Glaholm J; Leach MO; Collins D; al Jehazi B; Sharp JC; Smith TA; Adach J; Hind A; McCready VR; White H
    Br J Radiol; 1990 Jul; 63(751):547-53. PubMed ID: 2390689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-time follow-up of 5-fluorouracil metabolism in the liver of tumor patients by means of F-19 MR spectroscopy.
    Semmler W; Bachert-Baumann P; Gückel F; Ermark F; Schlag P; Lorenz WJ; van Kaick G
    Radiology; 1990 Jan; 174(1):141-5. PubMed ID: 2104675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitation of 5-fluorouracil catabolism in human liver in vivo by three-dimensional localized 19F magnetic resonance spectroscopy.
    Li CW; Negendank WG; Padavic-Shaller KA; O'Dwyer PJ; Murphy-Boesch J; Brown TR
    Clin Cancer Res; 1996 Feb; 2(2):339-45. PubMed ID: 9816177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients.
    Gieschke R; Burger HU; Reigner B; Blesch KS; Steimer JL
    Br J Clin Pharmacol; 2003 Mar; 55(3):252-63. PubMed ID: 12630975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil.
    Kamm YJ; Heerschap A; van den Bergh EJ; Wagener DJ
    Anticancer Drugs; 2004 Mar; 15(3):229-33. PubMed ID: 15014355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superiority of hepatic arterial infusion in preventing catabolism of 5-FU compared with portal vein infusion revealed by an in vivo 19F NMR study.
    Okuno K; Hirai N; Lee YS; Tarabar D; Ueno H; Yasutomi M
    Cancer Chemother Pharmacol; 1998; 42(4):341-4. PubMed ID: 9744781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective 19F MR imaging of 5-fluorouracil and alpha-fluoro-beta-alanine.
    Brix G; Bellemann ME; Zabel HJ; Bachert P; Lorenz WJ
    Magn Reson Imaging; 1993; 11(8):1193-201. PubMed ID: 8271906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.